ANNOUNCEMENT: Clinical Data and Specimens Available from Research Registry for Neonatal Lupus (RRNL)

The overall goal of the RRNL is to establish and maintain a database sufficiently rich to provide an invaluable resource to the academic community for translational research in the anticipation of curing this disease. Neonatal lupus is a model system for studying the potential role of autoantibodies in the pathogenesis of tissue injury in general. Understanding both the maternal and fetal contribution to risk of disease should provide insights on pathogenesis, diagnosis and therapy. Sufficient numbers of patients will facilitate better screening assays and clinical trials to evaluate evidence-based treatments. Moreover, because many mothers are indeed totally asymptomatic, neonatal lupus families offer a unique opportunity to study in parallel the natural history both of the autoantibody response and disease evolution. The RRNL and the RRNL Specimen Bank will thus serve as continued resources of patients and materials for basic and clinical studies conducted by approved investigators in the United States.

The RRNL under the directorship of Dr. Jill P. Buyon and supported by NIAMS, contains extensive clinical information on enrolled mothers and their affected children. Stored specimens are available from mothers and affected and unaffected children. DNA is being collected from all immediate and extended family members. The Registry welcomes applications from investigators interested in basic and clinical research.

Access Guidelines for preparation of Research Protocols to the Research Registry for Neonatal Lupus (RRNL) by clicking here.

If you have any questions on the preparation of a research protocol, please contact Tishaun Middleton at:


Designed by echopower for brains function design